Envision Healthcare (NYSE:EVHC)‘s stock had its “outperform” rating reiterated by stock analysts at Robert W. Baird in a research note issued to investors on Wednesday, The Fly reports. They presently have a $50.00 target price on the stock, up from their previous target price of $45.00. Robert W. Baird’s price target would indicate a potential upside of 19.90% from the stock’s previous close.
Other research analysts have also recently issued reports about the stock. Stephens restated a “hold” rating and issued a $34.00 price objective on shares of Envision Healthcare in a research report on Wednesday, January 10th. ValuEngine cut shares of Envision Healthcare from a “buy” rating to a “hold” rating in a research report on Friday, February 2nd. Canaccord Genuity restated a “buy” rating and issued a $46.00 price objective (up from $32.00) on shares of Envision Healthcare in a research report on Wednesday, February 28th. Zacks Investment Research upgraded shares of Envision Healthcare from a “strong sell” rating to a “hold” rating in a research report on Tuesday, January 2nd. Finally, KeyCorp set a $40.00 price objective on shares of Envision Healthcare and gave the stock a “buy” rating in a research report on Tuesday, November 14th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $42.57.
Shares of Envision Healthcare (EVHC) opened at $41.70 on Wednesday. Envision Healthcare has a 52-week low of $23.77 and a 52-week high of $67.73. The firm has a market capitalization of $4,886.35, a PE ratio of -20.14, a PEG ratio of 1.01 and a beta of 0.48. The company has a current ratio of 3.40, a quick ratio of 3.38 and a debt-to-equity ratio of 0.87.
Envision Healthcare (NYSE:EVHC) last announced its quarterly earnings results on Tuesday, February 27th. The company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.45 by $0.14. The firm had revenue of $2 billion for the quarter, compared to analysts’ expectations of $1.97 billion. Envision Healthcare had a positive return on equity of 4.62% and a negative net margin of 2.52%. The company’s revenue was up 68.0% on a year-over-year basis. During the same period in the prior year, the business posted $1.15 earnings per share. sell-side analysts predict that Envision Healthcare will post 3.33 EPS for the current year.
Several large investors have recently added to or reduced their stakes in EVHC. OZ Management LP purchased a new stake in shares of Envision Healthcare during the third quarter valued at approximately $131,987,000. Maverick Capital Ltd. lifted its stake in Envision Healthcare by 30.7% in the fourth quarter. Maverick Capital Ltd. now owns 10,002,182 shares of the company’s stock worth $345,675,000 after acquiring an additional 2,349,648 shares during the period. Guggenheim Capital LLC lifted its stake in Envision Healthcare by 140.4% in the fourth quarter. Guggenheim Capital LLC now owns 1,979,973 shares of the company’s stock worth $68,429,000 after acquiring an additional 1,156,381 shares during the period. Sapience Investments LLC lifted its stake in Envision Healthcare by 152.0% in the fourth quarter. Sapience Investments LLC now owns 1,127,610 shares of the company’s stock worth $38,970,000 after acquiring an additional 680,220 shares during the period. Finally, Douglas Lane & Associates LLC lifted its stake in Envision Healthcare by 512.8% in the fourth quarter. Douglas Lane & Associates LLC now owns 672,252 shares of the company’s stock worth $23,233,000 after acquiring an additional 562,554 shares during the period.
Envision Healthcare Company Profile
Envision Healthcare Holdings, Inc, formerly CDRT Holding Corporation, is a holding company. The Company, through its subsidiary, provides physician-led medical services in the United States. It operates in two segments: EmCare Holdings, Inc (EmCare) and American Medical Response, Inc (AMR). Its EmCare segment is a provider of integrated facility-based and post-acute care physician services to healthcare facilities in the United States.